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1 GENERAL PART  
1.1  Introduction  
1.1.1  Human Cytochrome P450 (CYP) Isoenzymes  
The human cytochrome P450 (CYP) isoenzymes are members of the 
superfamily of hemeproteins. They are components of the mixed-function oxidase 
systems and essential protein catalysts for the oxidative metabolism of many xeno- 
and endobiotics [1]. Two classes of CYPs are defined. The class I is located in 
bacteria and mitochondria. The human CYPs belong to class II, also known as 
microsomal CYPs [1]. To date 57 different human CYPs have been identified and 15 
of these isoenzymes are involved in the metabolism of xenobiotics. They are mainly 
located in the endoplasmic reticulum of liver cells. As depicted in Figure 1, CYP 
isoenzymes are responsible for about 75 % of the metabolism of xenobiotics [2]. 
Within these isoenzymes, nearly 100 % of the reactions are prepared by seven 
isoenzymes, namely CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, 
and CYP3A4. However the largest fraction of the CYP reactions was catalyzed by 
CYP3A isoenzymes [3]. Within these xenobiotic-metabolizing isoenzymes, CYP2C9, 
CYP2C19, and CYP2D6 were highly polymorphic expressed leading to different CYP 
activities. Poor metabolizers (PM) showed a complete lack of certain isoenzyme 
activity, intermediate metabolizers (IM) a decreased activity, the extensive 
metabolizers (EM) a normal activity, and the ultra-rapid metabolizers an increased 
activity [4]. As consequence, different plasma levels of the drugs and/or their 
metabolites can result varying from too low to too high. As shown in the study of 
Stamer et al., the same effect could be achieved by inhibition of the metabolizing 
enzyme [5], showing the importance of drug-drug interaction studies.  
2   
 
Figure 1: Elimination routes of drugs, adapted from Wienkers and Heath [2] 
 
1.1.2 Drug-Drug-Interactions  
Dug-drug interactions (DDI) were known as situation in which one drug 
influence the effect and/or the pharmacokinetics of co-administered drugs. 
These interactions could be caused e.g. by CYP inhibition or induction. 
Thereby, induction is defined as increase of enzyme amount as consequence 
of long-term drug exposure. In contrast, the inhibition of a CYP enzyme results 
in a decrease of the enzyme activity and thus, in a decreased metabolism rate 
of a drug by co-administered drug [6]. More and more patients are nowadays 
treated with more than one drug at the same time increasing the risk of DDI, 
which may lead to more frequent and longer hospitalization [7]. Population-
based studies between the early 1990’s and 2000’s showed that the amount of 
polypharmacy (prescribing of more than 5 drugs) and the associated DDI 
increased, illustrating the huge problem with DDI [8-11]. One popular example 
for such an interaction was described by Gasche et al. [12]. A patient under 
treatment with therapeutic doses of codeine and clarithromycin showed a 
narcotic syndrome. Clarithromycin inhibited CYP3A4, which was responsible 
for the demethylation of codeine to the inactive norcodeine. This led to an 
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increased metabolism rate to morphine by CYP2D6 and the patient was a CYP2D6 
ultra rapid metabolizer, which enhanced the morphine formation again. Furthermore 
he also was kidney insufficiency, leading to a reduction of the excretion of the active 
morphin-6-glucuronide. All these circumstances contributed the narcotic syndrome, 
but the CYP3A4 inhibition was a main part. However, DDI were not only between 
therapeutic drugs, but also between drugs, drugs of abuse, and food ingredients. 
Grapefruit juice is one important example [13]. The ingredients of this citrus fruit were 
able to inhibit CYP3A4 activity irreversible. Because the risk of adverse side effects 
by CYP inhibition is well known and documented, new therapeutic drugs have to be 
screened before approval. In contrast, new drugs of abuse were marketed and 
consumed without such testing. However, various studies have shown that drugs of 
abuse were CYP inhibitors comparable to known clinically relevant inhibitors [14-16]. 
 
1.1.3 In vitro CYP Inhibition Studies  
1.1.3.1 In Vitro Enzyme Kinetic Studies  
The knowledge about the Michaelis Menten constant (Km) of a respective 
biotransformation reaction is essential for the determination of the CYP inhibition 
using the inhibition constant 50 value (IC50) [17]. According to the U.S. Food and 
Drug Administration (FDA) guidance, the used model substrate concentration to 
determine the inhibition potential of a new substance should be at or below Km [17]. 
As a wide range of Km values are known for such substrates, the Km value should be 
evaluated for the used incubation system to guarantee the use of optimal substrate 
amount. The Km value is defined as the substrate concentration that will yield a 
reaction velocity that is half of the maximal velocity (Vmax) and reflects the substrate 
affinity to a certain enzyme. Conventional determinations of enzyme kinetic 
parameters are made by assessing the rate of product (metabolite) formation at 
several substrate concentrations [18]. The simplest model to describe enzymatic 
biotransformation and hence to calculate Km is fitting the initial rate velocities at 
various substrate concentrations to the Michaelis Menten equation (eq. 1).  
Venzyme = Vmax × [S] / (Km + [S])        (1) 
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For ideal determinations, the protein concentrations and incubation time should be 
within the linear range of metabolite formation, and in total, less than 20% of 
substrate should be consumed. 
 
1.1.3.2 In Vitro CYP Inhibition Assays  
For determination the in vitro inhibition potential of a substance, there were two 
assay opportunities: a single assay approach, monitoring every single isoenzyme 
activity separately or a cocktail approach, which is able to determine the inhibition 
potential against many isoenzymes at the same time [19-25]. For monitoring the 
isoenzyme inhibition, specific substrates are needed. Such a substance should show 
two characteristics, single CYP selectivity and simple metabolic scheme. These 
substrates were well studied and listed in a guidance of the FDA [7]. The second 
opportunity is time and cost saving, because fewer amounts of isoenzymes and 
cofactors are needed. Time efficiency can also be achieved because all interested 
isoenzymes could be monitored at the same time. However, the cocktail approach 
could have some limitations due to interferences between the specific substrates and 
metabolites, which have to be tested in advance. The interaction potential of 
bupropion, the CYP2B6 test substrate, with CYP2D6 was well documented [14]. 
Pooled human liver microsomes (pHLM) containing all relevant CYP isoenzymes 
were favored as isoenzyme source. The IC50 value is mainly used as constant to 
describe the inhibition potential [19-25]. The IC50 value represents the inhibitor 
concentration, at which the enzyme activity is reduced by 50 %. For that purpose, the 
metabolite concentration formed by the corresponding CYPs had to be determined in 
absence or presence of different inhibitor concentrations. Therefore, a multi-analyte 
approach is needed that allows quantifying low concentrations of the metabolites of 
all relevant CYP model substrates in the incubation mixtures besides the model 
substrates and inhibitors. For that application, LC-MS techniques were preferable 
used in lots of published assays [19-25]. The high sensitivity and selectivity of those 
techniques allowed quantification of metabolites especially if the turn-over rate was 
reduced by strong inhibition. Besides the test substrates, test inhibitors were also well 
studied [17]. These inhibitors were necessary for the evaluation of a new cocktail 
assay. The determined IC50 values of the cocktail assay could be confirmed by 
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comparing the values determined with single approach and with those given in the 
literature. These test inhibitors could also be used as positive control during 
isoenzyme incubations as described in part 2.2 [26]. 
 
1.1.4 In Vivo CYP Inhibition Studies  
In vivo studies were be performed if the in vitro data give hints for a CYP 
inhibition by the corresponding drug. The studies were generally designed to 
compare substrate concentrations with and without the in vitro tested inhibitor [27]. 
For the study design, crossover or parallel design is advised by the FDA. The 
crossover design is more efficient, but more time-consuming than the parallel design. 
Concerning the doses, the substrate and the inhibitor should be administered at 
therapeutic range. Another important part of the study design is the application way 
of the substrate and the inhibitor. To monitor a rapid reversible inhibition, the 
substrate and the inhibitor should be given simultaneously. To monitor a mechanism-
based inhibition, the inhibitor should be given prior to the substrate. Beside the right 
study design, the choice of the right test substrates is more important for in vivo 
studies than for in vitro studies. They should show the same characteristics as the in 
vitro test substrates. In addition their pharmacologic profile should be as harmless as 
possible. For in vivo CYP inhibition testing, the substrates could also be used in 
single assay or cocktail assay, as described in the literature [28, 29]. The advantages 
of the cocktail assay were the same as already described under 1.1.3.2 for the in 
vitro cocktail assays. For the in vivo testing of CYP1A2, caffeine is a suitable test 
substrate. It is exclusively metabolized by CYP1A2 in humans and rats and only the 
metabolite profile differs between these species [30].However, these differences did 
not influence the explanatory power by monitoring the pharmacokinetic parameters of 
caffeine. To give a statement about the inhibition potential of the tested drug, the 
area under the plasma concentration/time curve (AUC) of the test substrate could be 
used. The AUC could be calculated using the simple trapezoidal rule [31]. Reduced 
metabolism by inhibition leads to increased AUC. According to this increase the 
strength of the inhibitors can be classified. Strong inhibitors increased the AUC more 
than five times, moderate inhibitors more than two times, and weak inhibitors more 
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than one time. For CYP1A2, fluvoxamine is known as strong inhibitor [27] and can be 
used as test inhibitor to proof the study design. 
 
1.1.5 Drugs of Abuse  
In the last few years, the drugs of abuse (DOA) market was rapidly growing 
around the world [32, 33]. The early warning system of the European Monitoring 
Centre of Drugs and Drug Addiction (EMCDDA) reported 81 new psychoactive 
substances in 2013 in contrast to 15 in 2005. Most of the new substances were 
produced to get legal alternatives for controlled drugs [34], purchased via internet as 
so-called “legal highs” or as research chemicals. Most of these drugs belong to the 
groups of phenethylamines, piperazines, synthetic cannabinoids, or tryptamines [32]. 
A huge health risk arises from the fact that these substances are purchased and 
consumed without any safety testing. Therefore, no or only few data are available 
about the pharmacodynamic, -kinetic or the toxicological effects of these new 
substances. 
 
1.1.5.1 Methylendioxy-derived designer drugs  
The class of methylenedioxy-derived designer drugs (MDD) includes various 
families of compounds as given in Figure 2. Beside the classic amphetamine 
derivatives such as methylenedioxy-methamphetamine (MDMA), methylenedioxy 
derivatives of cathinones, piperazines, pyrrovalerones, and tryptamines appeared in 
the last few years. With the exception of the tryptamines, all derivatives act in the 
central nervous system (CNS) as stimulants affecting directly or indirectly the release 
or persistence of monoamine neurotransmitters such as serotonin (5-HT), 
noradrenalin (NA) and dopamine (DA) from presynaptic nerves [35]. In contrast, the 
tryptamines were 5-HT1A and 5-HT2A receptor agonists resulting in hallucinogenic 
effects [36]. According to the World and European Drug Report, the older 
methylenedioxy stimulants such as methylenedioxy-amphetamine (MDA), MDMA or 
methylenedioxy-ethylamphetamine (MDEA) were still in use [32, 33]. However only 
for MDMA, data about the CYP inhibition potential were available so far [37, 38]. But 
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in recent years, series of novel MDD came onto the DOA market [32]. Cathinones 
such as methylone and MDPV were sold as so-called “bath salts” via the internet and 
caused fatal poisonings [39-41]. To date, the knowledge about the interaction 
potential caused by CYP inhibition is not known for most of these compounds. Only a 
study about methylone could show that this compound also inhibited CYP2D6 activity 
as its amphetamine analogue MDMA [15]. Recently, benzofuranes could be detected 
in drug and human body samples as alternatives for MDMA [42-44]. They were not 
classic methylenedioxy-derived drugs, but as bioisosteric analogues, they can be 
assigned to this group [43]. The second oxygen of the methylenedioxy ring is 
substituted by one methine group, resulting in comparable effects of the CNS. 
Information about the pharmacological effects on neurotransmission was already 
known [43]. For all these described substances with the exception of MDMA and 
methylone, no data were available about the inhibition potential of the different CYP 
isoenzymes. 
 
 
Figure 2: Structures of methylenedioxy-derived designer drug classes 
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1.1.5.2 Tryptamine-derived designer drugs  
Biogenic tryptamines such as psilocybin and N,N-dimethyltryptamine (DMT) 
have been used since ancient times by South Americans for their hallucinogenic 
effects [36]. They act as agonist of the 5-HT2A receptor, resulting in mood, sensory 
perception, and thought changes. Today there were used as alternatives for 
traditional hallucinogens [45]. These substances as well as other hallucinogens like 
LSD were under legislative control, so users were searching for new, unscheduled 
alternatives. The market for newer tryptamines was opened. Alexander and Ann 
Shulgin synthesized hundreds of these substances and about 50 of them were 
psychoactive. They described the syntheses, doses and adverse side effects in their 
book “THIKAL” [46]. Several tryptamine-derived new psychoactive substances 
(TDNPS) such as alpha-methyl tryptamines (AMT), dimethyl tryptamines (DMT), 
diallyl tryptamines (DALT), and diisopropyl tryptamines (DiPT, structures given in 
Figure 3) entered the drugs of abuse market over the last few years. They were 
classified as one of the drug classes of the so-called New Psychoactive Substances 
(NPS). The recently published United Nations Office on Drugs and Crime World Drug 
Report [33] indicated that up to July 2012, twenty-five new tryptamines were reported 
by member states [33]. As mentioned above, most of them are not yet under 
legislative control and thus consumed as so-called “legal highs” purchased mainly via 
internet. A study evaluating legal high products available in the UK showed that 13 % 
of them contained hallucinogenic tryptamines [47]. Intoxication cases with 5-methoxy-
N,N-diisopropyl tryptamine (5-MeO-DiPT) were reported since the 2000’s [48-52]. 
The newer DALT analogue, 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT), caused 
fatal poisonings [53, 54]. Both, the reports about intoxications and the availability via 
internet, showed the distribution of these NPS. Again, they were also purchased and 
consumed without any pharmacologic safety testing. 
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Figure 3: Structures of some tryptamine-derived NPS 
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1.2 Aimes and Scopes  
As mentioned above, CYP isoenzymes are responsible for most of the 
metabolism of xenobiotics and endogenous molecules [1]. In vitro CYP 
inhibition cocktail assays are common approaches to test the inhibition 
potential of new drugs. New therapeutic drug candidates have to be tested 
before approval and corresponding data can be found e.g. in the Internet 
(http://medicine.iupui.edu/clinpharm/ddis/main-table/). In contrast, inhibition 
data of most new psychoactive substances are not available because such 
drugs are marketed and consumed without any safety pharmacology testing. 
Therefore, the aims of the presented studies were:  
 
- Development and validation of an LC-HR-MS/MS method to quantify low 
concentrations of the different CYP model metabolites in presence of 
the model substrates and inhibitors 
- Development and validation of an in vitro all-in-one CYP inhibition 
approach (cocktail approach) for assessing the inhibition potential of 
drugs of abuse 
- Determination of the CYP inhibition potential (IC50 value) of 
methylenedioxy-derived designer drugs of different drug classes 
- Determination of the CYP inhibition potential (IC50 value) of new 
psychoactive substances of the tryptamine class 
- Determination of the in vivo CYP1A2 inhibition potential of 5-MeO-DALT 
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2 PUBLICATIONS OF THE RESULTS  
The results of the studies were published in the following papers: 
 
2.1 Development and validation of a liquid-chromatography high-
resolution tandem mass spectrometry approach for quantification of nine 
cytochrome P450 (CYP) model substrate metabolites in an in vitro CYP 
inhibition cocktail [55]  
(DOI: 10.1001/S00216-014-7849-X) 
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2.2 Development of an in vitro cytochrome P450 cocktail inhibition 
assay for assessing the inhibition risk of drugs of abuse [26]  
(DOI: 10.1016/J.TOXLET.2014.08.004) 
  
16   
  
17   
2.3 In vitro cytochrome P450 inhibition potential of methylenedioxy-
derived designer drugs studied with a two cocktail approach [56]  
(DOI: 10.1007/s00204-014-1412-6) 
  
18   
  
19   
2.4  Cytochrome P450 inhibition potential of new psychoactive 
substances of the tryptamine class [57] 
(DOI 10.1016/j.toxlet.2015.11.013)  
20   
  
21   
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3 FINAL DISCUSSION AND CONCLUSIONS  
The presented studies showed that methylenedioxy-derived designer 
drugs as well as tryptamine-derived novel psychoactive substances were 
inhibitors of several CYP isoenzymes. The developed and validated LC-HR-
MS/MS approach was sensitive enough for the quantification of low substrate 
metabolite concentrations. Although some validation results were outside the 
acceptance criteria for one-point or/and full calibration, the method could be 
used for determination of IC50 values of the drugs of abuse. For O-deethyl 
phenacetin, 5-hydroxy omeprazole, O-demethyl dextromethorphan, and 6-
hydroxy chlorzoxazone, one-point calibration could be used for quantification 
without any problem. For the other analytes, one-point calibration could also 
be used, although some results were outside the acceptance criteria. Full 
calibration did not provide better results, but the calculation of IC50 values with 
the exception of N-deethyl amodiaquine was possible. However, a general 
statement of CYP 2C8 inhibition was also possible [55]. During the assay 
development, some interference between the substrates and metabolites 
could be detected. As consequence, the cocktail assay had to be split. 
However, the pooled mixture of both incubates could be analyzed in one 
analytical run. The new inhibition cocktail assay was comparable with single 
assay results, reproducible, and applicable for testing the inhibition potential of 
drugs of abuse [26]. All of the tested methylenedioxy-derived designer drugs 
inhibited CYP2D6 activity. In addition correlations between the IC50 value and 
the structural properties could be seen. Therefore, it seemed that the inhibition 
potential of substances with unsubstituted amine function decrease compared 
to those with lipophilic substituent. This could be seen for the amphetamine 
types as well as for the cathinones. A second correlation was that the IC50 
values decreased from drugs with methyl to those with ethyl side chains in 
alpha position. For the 2,3-methylenedioxy compounds the values were 
smaller than that for the 3,4-substituted analogues. Concerning the 
benzofurans, bioisosteric derivatives of 3,4-MDA and 3,4-MDMA, the IC50 
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values decreased from the amphetamines to the benzofurans. The additional 
beta-keto function of the cathinones led to an increased inhibition against 
CYP2D6 in comparison to the amphetamines. This beta-keto group was also 
responsible for the CYP2B6 inhibition in contrast to the amphetamines, which 
showed no inhibition on that isoenzyme. Further six drugs showed inhibition of 
the CYP1A2 activity, three of CYP2A6 activity, 13 of CYP2B6 activity, two of 
CYP2C9 activity, six of CYP2C19 activity, one of CYP2E1 activity, and six of 
CYP3A activity [56]. Concerning the tryptamines, all tested TDNPS with the 
exception of DMT showed more or less inhibition potential against the various 
CYP isoforms. The following drugs showed inhibition of the activity of the given 
CYPs, which might be clinically relevant: CYP1A2, 4-MeO-AMT, 5-F-2-Me-
AMT, 5-Cl-AMT, 6-F-AMT, 7-Me-AMT, all DALTs; CYP2A6, AMT, 6-F-AMT; 
CYP2D6, AMT, 5-F-AMT, 5-F-2-Me-AMT, 5-Cl-AMT, all DALTs, 4-HO-DiPT; 
CYP2E1, 5-Me-DALT, 5-MeO-DALT, 5-MeO-2-Me-DALT; CYP3A, 5-F-2-Me-
DALT, 5-Cl-DALT, 5-Br-DALT, 5-Me-DALT, 6-F-DALT [57]. In addition to this 
in vitro data of the TDNPS, the inhibition potential of 5-MeO-DALT could be 
confirmed by an in vivo experiment using rats and caffeine as probe substrate. 
The kinetic parameters of caffeine changed with the coadministration of 5-
MeO-DALT as expected from the in vitro results. Because of the inhibition 
potential in the range of clinical relevant inhibitors and plasma concentrations 
similar to them, CYP inhibition by MDD and TDNPS might be clinically relevant 
[56]. Thus, they could change the pharmacokinetics, namely the plasma levels 
and the corresponding effects of co-administered therapeutics or NPS. 
Prodrugs such as tramadol, mainly metabolized by one isoenzyme, could lose 
their potency, if bioactivation was blocked [5]. However, it should be kept in 
mind that clinical cases or studies would be desirable to assess the risks 
associated with drug-drug interactions. 
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5 ABBREVIATIONS  
AMT   Alpha-methyl tryptamine 
AUC   Area under the plasma concentration/ time curve 
CNS   Central nervous system 
CYP   Cytochrome P450 
DA   Dopamine 
DALT   Diallyl tryptamine 
DDI   Drug-drug-interactions 
DiPT   Diisopropyl tryptamine 
DMT   N,N-Dimethyltryptamine 
DOA   Drugs of abuse 
EMCDDA  European Monitoring Centre of Drugs and Drug Addiction 
5-HT   Serotonin 
IC50   Inhibition constant 50 
Km   Michaelis Menten constant 
LC   Liquid chromatography 
MDA   methylenedioxy-amphetamine 
MDD   Methylenedioxy-derived designer drugs 
MDEA  methylenedioxy-ethylamphetamine 
MDMA  methylenedioxy-methamphetamine 
5-MeO-DALT 5-methoxy-N,N-diiallyl tryptamine 
5-MeO-DiPT 5-methoxy-N,N-diisopropyl tryptamine 
MS   Mass spectrometry 
NA   Noradrenaline 
NPS   New psychoactive substances 
TDNPS  tryptamine-derived new psychoactive substances 
Vmax   Maximal velocity 
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6 SUMMARY  
In the presented studies, a CYP inhibition cocktail assay was developed 
and validated. The LC-HR-MS/MS method was able to quantify low 
concentrations of the metabolites using a one-point calibration model. During 
development, the cocktail assay showed interferences between the substrates 
and metabolites. It was spilt into cocktail A consisting of phenacetin, coumarin, 
diclofenac, dextromethorphan, and testosterone and cocktail B of bupropion, 
amodiaquine, omeprazole, and chlorzoxazone. Using these sets, the IC50 
values of specific test inhibitors were comparable with the values determined 
with a single approach and with those given in the literature. Altogether, the 
new assay provided valid, reproducible, and applicable results. All the tested 
drugs of abuse showed inhibition against at least one isoenzyme. The 
methylenedioxy-derived designer drugs inhibited CYP2D6 activity with values 
comparable to paroxetine or fluoxetine. The methylendioxy-
ethylphenethylamines showed the highest potential against CYP2D6. The 
cathinones showed also inhibition on the CYP2B6 activity comparable to 
efavirenz. Overall, CYP1A2, CYP2A6, 2B6, 2D6, and CYP3A4 were inhibited 
similar to known inhibitors. The tested DALTs showed the strongest inhibition 
against CYP1A2, CYP2D6, and CYP3A activity similar to known inhibitors. For 
5-MeO-DALT, CYP1A2 inhibition could also be shown during an in vivo 
experiment with rats as expected from the in vitro results. 
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7 ZUSAMMENFASSUNG 
 
Diese Dissertation beschreibt die Entwicklung und Validierung eines CYP 
Inhibitions-Cocktail-Assay. Die LC-HR-MS/MS Methode erlaubte niedrige 
Konzentrationen an Metaboliten mittels Ein-Punkt-Kalibration zu bestimmen. 
Während der Entwicklung zeigte der Cocktail-Assay Interferenzen zwischen 
den Substraten und den Metaboliten. Daher wurde der Assay in Cocktail A 
und B aufgetrennt. Cocktail A beinhaltete Phenacetin, Coumarin, Diclofenac, 
Dextromethorphan und Testosterone und Cocktail B Bupropion, Amodiaquine, 
Omeprazole und Chlorzoxazone. Unter Verwendung dieser beiden Sets waren 
die bestimmten IC50 Werte vergleichbar mit den Werten aus einem Single-
Assay und mit denen der Literatur. Zusammenfassend war der neuen Assay in 
der Lage valide, reproduzierbare und verwendbare Ergebnisse zu liefern. Die 
getesteten Missbrauchsdrogen zeigten alle eine Hemmung gegen mindestens 
ein Isoenzym. Die Methylendioxy Designer-Drogen hemmten CYP2D6 mit 
Werten vergleichbar mit Paroxetin oder Fluoxetin. Die Methylenedioxy-
Ethylphenethylamine zeigten das höchste Potenzial gegen CYP2D6. Die 
Cathinone zeigten ebenfalls eine Inhibition gegen CYP2B6 vergleichbar zu 
Efavirenz. Insgesamt wurden CYP1A2, CYP2A6, CYP2B6, CYP2D6 und 
CYP3A vergleichbar zu bekannten Hemmstoffen gehemmt. Die getesteten 
DALTs zeigten die stärkste Hemmung gegen CYP1A2, CYP2D6 und CYP3A 
wie bekannte Hemmstoffe. Die CYP1A2 Hemmung von 5-MeO-DALT konnte 
auch in vivo mit Ratten gezeigt werden. 
 
